Adopting the Evolving Management of HR+/HER2-mBC into Practice

著者: Annenberg Center for Health Sciences
  • サマリー

  • Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
    Annenberg Center for Health Sciences
    続きを読む 一部表示

あらすじ・解説

Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
Annenberg Center for Health Sciences
エピソード
  • Therapeutic Approaches for the Treatment of Patients with HR+/HER2- mBC
    2025/04/09

    Therapeutic Approaches for the Treatment of Patients with HR+/HER2- mBC

    続きを読む 一部表示
    21 分
  • Navigating Through the Current Treatment of Patients with HR+/HER2- mBC
    2025/04/09

    Navigating Through the Current Treatment of Patients with HR+/HER2- mBC

    続きを読む 一部表示
    7 分
  • Molecular and Tumor Profiling
    2025/04/09

    Molecular and Tumor Profiling

    続きを読む 一部表示
    23 分

Adopting the Evolving Management of HR+/HER2-mBC into Practiceに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。